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SUMMARY
The Drosophila transcription factor Prospero functions as a tumor suppressor, and it has been suggested
that the human counterpart of Prospero, PROX1, acts similarly in human cancers. However, we show here
that PROX1 promotes dysplasia in colonic adenomas and colorectal cancer progression. PROX1 expression
marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human
colorectal tumor xenografts and intestinal adenomas in Apcmin/+ mice, while its transgenic overexpression
promotes colorectal tumorigenesis. Furthermore, in intestinal tumors PROX1 is a direct and dose-dependent
target of the b-catenin/TCF signaling pathway, responsible for the neoplastic transformation. Our data under-
score the complexity of cancer pathogenesis and implicate PROX1 in malignant tumor progression through
the regulation of cell polarity and adhesion.INTRODUCTION
Colorectal cancer (CRC) is the second most common type of
malignancy in the Western world. In CRC development, a pre-
neoplastic polyp gradually accumulates genetic changes that al-
low uncontrolled proliferation and cell survival, followed by inva-sive and metastatic properties typical of carcinoma. Activation of
the APC/b-catenin/TCF pathway is an initiating event in the ma-
jority of human CRCs (reviewed in Kinzler and Vogelstein, 1996;
Weinberg, 2007). The APC protein binds cytoplasmic b-catenin
targeting it for degradation. If the degradation is inhibited, for
example, following Wnt signals, b-catenin accumulates in theSIGNIFICANCE
Understanding the mechanisms that control tumor progression beyond the initiating events, such as activation of TCF/
b-catenin signaling in colorectal cancer, is important for the development of cancer therapies. Here we show that the tran-
scription factor PROX1, previously shown to play an essential role in the development of liver, lymphatic vasculature, and
eye, is an important regulator of progression from a benign to a highly dysplastic phenotype in colorectal tumors. This result
uncovers a cancer- and tissue-specific effector of the TCF/b-catenin cascade and suggests that PROX1 is a potential target
for the development of colon cancer therapy.Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc. 407
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tors to control gene expression. Familial adenomatous polyposis
patients, who have APC mutations that block b-catenin degra-
dation, develop hundreds of intestinal polyps and progress to
CRC by the age of 40. At least one APC allele is mutated in about
60% of sporadic CRCs, and somatic b-catenin mutations are
found in 50% of CRCs that have wild-type APC alleles.
An immediate consequence of loss of Apc in the normal
mouse intestinal epithelium is the expansion of the progenitor
cell population, in agreement with the in vitro studies showing
that the b-catenin/TCF pathway controls colon cancer cell prolif-
eration and expression of progenitor cell-specific genes (San-
som et al., 2004; van de Wetering et al., 2002). The C-myc tran-
scription factor, which is a direct target of b-catenin/TCF, is
largely responsible for the increased cell proliferation and apo-
ptosis and loss of cell migration and differentiation after Apc de-
letion (Sansom et al., 2007). However, in humans, several years
are required for the complex multistage progression of APC mu-
tant tumors from benign adenoma to carcinoma in situ and finally
to metastatic cancer. Knowledge of the molecular regulation of
these transitions is still incomplete. Here we show that the ho-
meobox transcription factor PROX1 is an intestinal-specific tar-
get of the b-catenin/TCF pathway and that it is essential for the
transition from benign to severe dysplasia, which is associated
with a high risk of subsequent colon carcinoma.
PROX1 is an evolutionarily conserved transcription factor that
controls neural precursor cell development in Drosophila, and
lymphatic endothelial and retinal progenitor cell differentiation
and the development of the liver and lens in mice (Chu-Lagraff
et al., 1991; Dyer et al., 2003; Oliver et al., 1993; Sosa-Pineda
et al., 2000; Wigle et al., 1999; Wigle and Oliver, 1999). The Dro-
sophila counterpart of PROX1, Prospero, acts as a brain tumor
suppressor by preventing neuroblast self-renewal (Betschinger
et al., 2006). It has recently been suggested that PROX1 has
a similar role in human cancers. Decreased PROX1 levels were
observed in hepatocellular carcinomas and biliary duct cancers,
concomitantly with loss of heterozygosity and epigenetic silenc-
ing of PROX1 (Laerm et al., 2007; Shimoda et al., 2006). We have
investigated the expression of PROX1 in other common human
cancers and noticed that it is overexpressed in the majority of
CRCs. Here we explore this observation and report findings
showing that PROX1 is a target of the b-catenin/TCF pathway
in CRC, where it promotes dysplasia, tumor growth, and malig-
nant progression.
RESULTS
PROX1 Is Overexpressed in Human CRC
In a cancer gene profiling array, which contains cDNAs repre-
senting 241 human cancers and corresponding normal tissues,
PROX1 mRNA was significantly increased in 35 of 53 CRC sam-
ples, but not in breast, uterine, lung, kidney, ovarian, or thyroid
tumors (Figures 1A and 1C). PROX1 is a marker for lymphatic
vessels, which are abundant in normal colonic submucosa and
around colon carcinomas. However, hybridization with a probe
for the lymphatic endothelial hyaluronan receptor LYVE-1 indi-
cated that the increased expression of PROX1 in CRC can-
not be attributed to the lymphatic vessels in the tumors
(Figure 1B). PROX1 mRNA was also present in the CRC cell lines408 Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc.SW480, SW48, COLO205, LS174T, and HT-29, but not in the cell
lines DLD1, WiDr, HCT-116, or SW403, or 18 other non-CRC cell
lines (Figure S1 available online). PROX1 cDNA from SW480,
COLO205, and LS174T cells did not contain coding region mu-
tations, suggesting that PROX1 retains its wild-type function
(H. Kubo, personal communication).
Immunohistochemical staining revealed increased PROX1
expression in 13/16 adenomas and in 16/24 adenocarcinomas,
while only rare scattered PROX1-positive cells were observed
in normal colonic epithelium or in hyperplastic polyps (Figure S2
and data not shown). High PROX1 levels were observed in
the majority of cells in nine adenomas and in six carcinomas,
whereas in the other lesions heterogeneous expression of
PROX1 occurred. In four carcinoma samples no staining for
PROX1 was seen, except in the lymphatic vessels (data not
shown).
In colon adenoma samples containing both low- and high-
grade dysplasia (n = 5), the highest levels of PROX1 were
observed in the areas of severe dysplasia, characterized by dis-
ruption of the glandular architecture, crowding, and prominent
cellular atypia (Figures 1D and 1E). PROX1-positive cells were
also strongly positive for nuclear b-catenin, a hallmark of acti-
vated Wnt signaling. Notably, we observed glands that con-
tained small clusters or isolated PROX1 and nuclear b-catenin-
positive cells along with areas that were almost entirely positive
for both of these proteins, suggesting that these glands are un-
dergoing clonal selection toward a highly dysplastic phenotype
(Figure 1F).
The tumor suppressor p53 is commonly mutated in CRC, and
mutated p53 is overexpressed in highly dysplastic adenomas
(Saleh et al., 1998). Although PROX1 and p53 were located in
overlapping sets of cells in the highly dysplastic regions
(Figure S2), isolated clusters of Prox1 and nuclear b-catenin-
positive cells expressed only low levels of p53, suggesting that
PROX1 upregulation occurs prior to p53 mutation (Figure S2).
Collectively, the data suggested that PROX1 upregulation de-
fines the transition from adenoma to carcinoma in situ and that
it plays a role in the b-catenin/TCF-dependent progression of
colon cancer.
Prox1 Is Overexpressed in Mouse Models of Intestinal
Cancer with Activated TCF/b-Catenin Signaling
Azoxymethane (AOM) induces colon cancer in rodents through
the development of microscopic lesions, aberrant crypt foci
(ACFs), which further progress to colon adenomas and carcino-
mas (Boivin et al., 2003). These neoplasms are morphologically
similar to human CRC, including abnormal activation of the
b-catenin/TCF pathway (Sheng et al., 1998). In a genetic model
of intestinal neoplasia, the Apcmin/+ mice carry a germline mu-
tation in Apc, which, together with somatic inactivation of the
remaining wild-type allele, leads to abnormal b-catenin/TCF
signaling and development of multiple polyps in the small intes-
tine (Su et al., 1992).
We observed high Prox1 levels in intestinal neoplasms of both
AOM-treated and Apcmin/+ mice (Figures 2A–2C and Figure S3).
Prox1 was present in tumor cells with high cytoplasmic and nu-
clear b-catenin, but not in cells of normal glands with membrane
localization of b-catenin (Figures 2D–2G). Notably, Prox1 expres-
sion was heterogeneous in small adenomas of the Apcmin/+ mice
Cancer Cell
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cells have a selective growth advantage (Figure S3). Interestingly,
while all Prox1-positive cells were positive for nuclear b-catenin,
some cells with high nuclear b-catenin did not express Prox1,
suggesting that additional factors are necessary for its expres-
sion, or that the degree of activation of the TCF/b-catenin path-
way varies even in the presence of abundant nuclear b-catenin.
Mutations in components of the TGFb pathway, such as
TGFBRII and SMAD4, occur in human CRC, and inactivation of
the TGFb1-binding protein Ltbp4 leads to CRC in mice
(Sterner-Kock et al., 2002). However, Prox1 was absent from co-
lonic adenocarcinomas of Ltpb4/ mice, which had a normal
distribution of b-catenin (Figure S3 and data not shown). Simi-
larly, we did not observe Prox1 overexpression in gastric adeno-
mas from intestinal trefoil factor 1-deficient mice (data not
shown). These results suggested that Prox1 is located down-
stream of the APC/b-catenin/TCF pathway in vivo.
PROX1 Is Induced in Nascent Microadenomas
but Not in the Expanded Progenitor Cell Population
following Somatic Deletion of Apc
To pinpoint at what stage of tumor development Prox1 expres-
sion is activated, we used a mouse model where deletion of
Figure 1. PROX1 Is Overexpressed in
Human Colorectal Cancer and Severe
Dysplasia
(A and B) A cancer gene-profiling array was hy-
bridized to probes for PROX1 (A), and the lym-
phatic endothelial marker LYVE-1 (B).
(C) Quantification of the dot blot in (A); data are
normalized to GAPDH levels from the same blot
and presented as mean ± SD. RU, relative units.
Asterisks in (A) and (B) indicate a colon sample.
Asterisks in (C) indicate samples in which PROX1
expression is significantly different from that of
the normal tissue (p < 0.05).
(D) PROX1 is induced upon transition to carcinoma
in situ. Staining for PROX1 (brown) of colon polyp
harboring both low- and high-grade dysplasia.
(E) High-power magnification of the inset in (D) and
adjacent section stained with hematoxylin and eo-
sin shows severely disturbed glandular architec-
ture in PROX1-positive area.
(F) PROX1-positive cells contain high levels of cy-
toplasmic and nuclear b-catenin. Asterisk, normal
colonic gland.
Scale bars, 100 mm in (D), 25 mm in (E) and (F).
Apc in intestinal epithelium is induced
by b-naphtoflavone. Loss of Apc leads
to a rapid and drastic expansion of the
progenitor cell compartment in the
crypts, followed by formation of wide-
spread micro and macroadenomas (San-
som et al., 2004). After 5 days of b-naph-
toflavone treatment, Prox1 was not
induced in expanded proliferating crypts,
instead it was present in the dysplastic
epithelium that began to outpocket into
the surrounding stroma and to form microadenomas (Figures
2H and 2J). Strikingly, Prox1 was expressed in the majority of
highly dysplastic epithelial cells 6 days after induction (Figure 2I).
These data further confirm that Prox1 lies downstream of the ac-
tivated TCF/b-catenin pathway and show that either additional
signals or prolonged and very high levels of TCF/b-catenin sig-
naling are necessary for Prox1 induction in the initiated progen-
itor cells. Most importantly, together with the high levels of Prox1
in Apc-deficient macroadenomas and human colon carcinomas
in situ, these results implicate Prox1 in tumor establishment,
maintenance, and/or progression rather than in the regulation
of normal progenitor cell phenotype or cancer initiation.
Prox1 Is Expressed in a Subset of Enteroendocrine
Cells and Their Progenitors in Normal Intestinal
Epithelium
Intestinal epithelium is composed of slowly dividing stem cells
located at the bottom of the crypts, the transient amplifying cells,
which give rise to the enterocytes, goblet, enteroendocrine, and
Paneth cells, and terminally differentiated cells, located in the lu-
minal part of the colon or villi in the small intestine. In mouse in-
testine Prox1 was present in scattered cells in the villi and crypts
(Figure 3A). Enteroendocrine cells that expressed hormones
PYY, cholecytokinin (CCK), and glucagon-like peptide-1 (GLP-1)Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc. 409
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nin-expressing cells were only rarely Prox1-positive (<10%)
(Figures 3C–3E and data not shown). In addition, a subset of
Prox1-positive cells in the crypts expressed enteroendocrine
progenitor marker neurogenin-3 (Ngn3), but not the Paneth cell
marker lysozyme (Figures 3C–3E). Unlike Prox1-positive cells
in intestinal adenomas, Prox1-positive cells in the normal gut
did not proliferate, as determined by BrdU uptake or staining
for phosphohistone H3 (Figure 3B and data not shown). In agree-
Figure 2. Prox1 Is Overexpressed in Mouse Tumors with Activated
TCF/b-Catenin Signaling
(A and B) Prox1 (brown nuclear staining) is expressed in colonic neoplasms
from Apcmin/+ and AOM-treated mice.
(C) High Prox1 mRNA levels in Apcmin/+ adenoma. T, tumor; N, normal.
(D) Increased cytoplasmic and nuclear b-catenin (red) in AOM-induced
adenoma. Asterisk, normal intestinal gland.
(E) Double staining of AOM-induced lesion for b-catenin (red) and Prox1
(green).
(F and G) Prox1 is present in tumor cells with high nuclear b-catenin.
High-power view of the white squares in (D) and (E).
(H–J) Prox1 is induced in dysplastic epithelial cells (arrows in [H]) but not the
expanded progenitor population following immediate Apc deletion. Staining
for Prox1 (red) in small intestine of Apcflox;flox; AhCre and control mice after 5
and 6 days of treatment with b-naphtoflavone. lv, Prox1-positive lymphatic
vessels.
Scale bars, 20 mm in (A) and (B), 10 mm in (D)–(G), 25 mm in (H)–(J).410 Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc.ment with these data, Prox1-positive cells were absent from the
intestinal epithelium of neonatalNgn3/ mice, which lack enter-
oendocrine cells (Jenny et al., 2002; Figures 3F and 3G). A similar
expression pattern was observed in human colon and small in-
testine, where nonproliferating PROX1-positive cells were found
to reside both in the crypt and in differentiated compartment, and
a subset of cells expressed the neuroendocrine marker chro-
mogranin A (Figures 3H–3J). The data show that in the normal
intestinal epithelium Prox1 is mainly produced in a subset
of mature enteroendocrine cells as well as either in Ngn3+ enter-
oendocrine precursors undergoing terminal differentiation or in
long-lived enteroendocrine progenitors (Bjerknes and Cheng,
2006).
The b-Catenin/TCF Pathway Controls PROX1
Expression in CRC
The CRC cell line SW480, which we found to be PROX1 positive
(Figure S1), contains two cell populations: epithelial-like slowly
growing adherent cells (A) and weakly adherent rounded cells
(R), which form aggressive tumors and are resistant to vitamin
D-induced growth arrest and differentiation (Palmer et al.,
2001; Tomita et al., 1992). PROX1 was strongly expressed only
in the R cells (Figure S4). We isolated several clones of
SW480R PROX1-positive and SW480A PROX1-negative cells
and confirmed their common origin using microsatellite analysis
(Figure S4 and Supplemental Experimental Procedures). As ex-
pected (Palmer et al., 2001; Tomita et al., 1992), SW480R but
not SW480A cells formed rapidly growing tumors when im-
planted subcutaneously in nu/nu mice (0.73 ± 0.3 g versus
0.03 ± 0.01, respectively, n = 6, p < 0.05 at 28 days). Moreover,
when a 50%–50% mixture of SW480R and SW480A cells was
implanted, only PROX1-positive SW480R cells were recovered
from the subsequent tumors, demonstrating that these cells
have a selective growth advantage in vivo (data not shown).
The gene expression profile of SW480R versus SW480A cells
correlated with the aggressive and adhesion-independent tumor
phenotype. Notably, SW480R cells lacked many components of
the actin, intermediate filament, and microtubule networks, such
as gelsolin, filamins A and B, ezrin, moesin, vimentin, integrins,
and tubulins (Table S1 and data not shown); they expressed
higher levels of the proto-oncogene CMET and the receptor ty-
rosine kinase FGFR4, which is associated with malignant trans-
formation in colorectal carcinomas (Bange et al., 2002) and had
lower levels of cell-cycle inhibitor CDKN1a (p21CIP1/WAF1) and
metalloprotease inhibitor TIMP-3 (Figure S4).
Because the activation of b-catenin/TCF signaling correlated
strongly with PROX1 expression in the in vivo samples, we stud-
ied the relationship of PROX1 with this pathway. Suppression of
PROX1 in SW480R cells using two different siRNAs did not affect
b-catenin/TCF-responsive reporter activity, the nuclear localiza-
tion, or the levels of active, nonphosphorylated b-catenin (Fig-
ure S5 and Figure 4A). In contrast, suppression of b-catenin
resulted in almost complete loss of PROX1 expression (Fig-
ure 4A). Suppression of PROX1 was also observed in SW480R
cells transfected with a dominant-negative mutant of TCF4,
which disrupts b-catenin/TCF-mediated transcription (Fig-
ure 4B). However, p21CIP1/WAF1 overexpression that induces
growth arrest and differentiation of CRC cells (van de Wetering
et al., 2002) did not alter PROX1 levels (Figure 4B). Taken
Cancer Cell
PROX1 Promotes Colorectal Tumor ProgressionFigure 3. PROX1 Expression in Normal Intestinal Epithelium
(A) Prox1-positive cells (brown, arrows) are present in the crypts and villi in mouse small intestine.
(B) Prox1-positive cells in the crypt (red, arrow) are located below the proliferation zone, identified by staining for BrdU after 120 min pulse labeling (green). lv,
lymphatic vessel.
(C–E) Staining for Prox1 (red) and Ngn3, PYY, or lysozyme (green).
(F and G) Prox1 expression is lost in duodenal epithelium ofNgn3/ mice but maintained in lymphatic vessels ofNgn3/ and control wild-type mice. Staining for
Prox1 (red) and the lymphatic marker LYVE-1 (green).
(H and I) Some PROX1-positive cells (red) in human colon (H) and small intestine (I) express chromogranin A (green).
(J) Prox1-positive cells (red) are located below the Ki67+ proliferation zone (green) in human small intestine (only an intestinal crypt is shown).
Nuclei are stained blue with Hoechst 33342 in (B) and (H)–(J). Scale bars, 25 mm.together with the in vivo expression data, these results show that
PROX1 lies downstream of b-catenin/TCF signaling.
Although b-catenin/TCF signaling was necessary for PROX1
expression in the SW480R cells, PROX1 levels were low in
SW480A cells carrying the same inactivating mutation of APC.
As the SW480R cells displayed a two-fold higher activation of
the TCF-responsive promoter TopFLASH and higher levels of
both total and active b-catenin (Figure 4C), we hypothesized
that PROX1 expression is induced only in cells with high levels
of b-catenin/TCF activity. Indeed, transfection of SW480A cells
with constitutively active LEF1-b-catenin fusion construct in-
creased TopFLASH reporter activity 11.3 ± 2.9-fold in compar-
ison to GFP-transfected cells. Furthermore, overexpression of
LEF1-b-catenin induced PROX1 in transfected cells, while over-
expression of GFP had no effect (Figure 4D, 38% versus 1%
PROX1-positive transfected cells in two independent experi-
ments). These findings suggested that only high levels of b-
catenin/TCF activation induce PROX1 in CRC.
To determine if PROX1 is a direct target of TCF/b-catenin,
we searched the PROX1 promoter/enhancer regions for evolu-
tionary conserved TCF/LEF binding sites (Hallikas et al., 2006).
Analysis of human, rat, and mouse sequences identified two
conserved TCF/LEF binding sites at 43 kb and 49 kb rela-
tive to the human PROX1 start codon (Figure S6). Electropho-
retic mobility shift assay experiments with nuclear extractsfrom SW480R cells and DNA oligonucleotide sequences from
PROX1 enhancer regions confirmed specific affinity only to
the 49 kb TCF/LEF binding site, as shown by the competition
and supershift experiments (Figure 4E and data not shown).
Furthermore, in luciferase reporter assays, cotransfection with
LEF-1-b-catenin fusion protein strongly increased only the ac-
tivity of the 49 kb-luc fragment (Figure S5). Finally, using
chromatin immunoprecipitation (ChIP) we showed that endog-
enous TCF4 binds specifically to the 49 kb element in
SW480R cells, while no interaction was observed in PROX1-
negative SW480A and HCT116 cells (Figure 4F). At the same
time, TCF4 interacted with TCF/LEF site in CMYC promoter
in all three cell types, in agreement with previous reports (Beiter
et al., 2005). These results suggested that PROX1 transcription
is directly regulated by TCF/b-catenin signaling through the
TCF/LEF binding sites of the 49 kb PROX1 element. In
PROX1-negative CRC cells, this element may be inaccessible
to TCF/LEF/b-catenin, while becoming available via further
increased TCF/b-catenin signaling (Figure 4D). Although alter-
native explanations are possible, we suggest that prolonged
exposure of progenitor cells to TCF/b-catenin signaling, as
observed in the Apcflox/flox;Ah-Cre mice, predisposes them
for further epigenetic changes facilitating access to the 49
kb enhancer and leading to Prox1 expression in nascent
adenomas.Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc. 411
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in Liver Cancer
Stabilizing mutations of b-catenin are frequently found in human
liver cancer, and loss of Apc leads to liver tumors in mice (Colnot
et al., 2004). On the other hand, decreased expression of PROX1
was recently reported in advanced liver cancer (Shimoda et al.,
2006). Although the hepatocellular carcinoma HepG2 cells con-
tain mutated b-catenin and high levels of PROX1 (de La Coste
et al., 1998; and this study), dnTCF4 transfection did not affect
their PROX1 expression, indicating that TCF/b-catenin does not
control PROX1 in these cells (Figure5A).Because the Ah promoter
is activealso inhepatocytes (Ireland et al., 2004), we could confirm
that loss of Apc in hepatocytes ofAh-Cre; Apcflox/flox mice did not
increase Prox1 expression, in spite of the nuclear translocation of
b-catenin (Figures5B and 5C). Thus, in response toactivatedTCF/
b-catenin signaling, PROX1 expression is triggered only in a spe-
cific cellular context, such as in CRC, and this pathway does not
control PROX1 expression in normal or transformed hepatocytes.
Figure 4. High Levels of b-Catenin/TCF
Signaling Are Necessary for PROX1 Expres-
sion in CRC Cells
(A) Loss of b-catenin inhibits PROX1 expression in
CRC cells. Northern and western blots of SW480R
cells transfected with GFP siRNA A18, b-catenin
siRNAs A32 and A33, or PROX1 siRNAs A16 and
A25, or left untreated (NT).
(B) Dominant-negative TCF4 (dnTCF4) but not
p21CIP1/WAF1 suppresses PROX1 in SW480R cells.
Staining for dnTCF4 or p21CIP1/WAF1 (red), PROX1
(green), and DNA (blue).
(C) SW480R cells display higher TOPFlash re-
porter activity and active and total b-catenin than
SW480A cells. Data in the graphs are shown as
mean ± SD.
(D) Increased b-catenin/TCF signaling induces
PROX1. Staining for PROX1 (red) in SW480A cells
transfected with LEF1-b-catenin or GFP (green).
(E) Electrophoretic mobility shift assay of the 49
kb enhancer region of PROX1 containing TCF/LEF
binding site. Nuclear extracts were from SW480R
cells transfected with myc-tagged LEF1-b-catenin
fusion construct. 1, no extract; 2, wild-type (WT)
sequence; 3, competition with unlabeled WT se-
quence; 4, competition with unlabeled TCF/LEF
site mutant sequence; 5, supershift with anti-
myc antibody; 6, supershift with b-catenin anti-
body (arrow); 7, supershift with control mouse
antibody.
(F) Detection of occupancy of the 49 and 43 kb
PROX1 enhancers by TCF4. Chromatin immu-
noprecipitation from SW480R, SW480A, and
HCT116 cells with TCF4-specific or control anti-
bodies. PCR for the indicated genomic regions;
CMYC promoter region, known to bind TCF4
(Beiter et al., 2005), and exon 6 of GAPDH served
as positive and negative controls.
Scale bars, 25 mm.
PROX1 Controls Cell Adhesion
Program in CRC
PROX1 was previously reported to
control the proliferation of lens fiber cells
and the exit of retinal progenitor cell from the cell cycle (Dyer
et al., 2003; Wigle et al., 1999). To understand the role
of PROX1 in CRC, we studied the transcriptional profile of
SW480R cells 48 hr after PROX1 gene silencing with two
PROX1 siRNAs (Figure 6A and Figure S7). Using a false discov-
ery rate of <0.05 and 2-fold change as cut-off values, 117 genes
were upregulated and 31 downregulated following loss of
PROX1 (Table S2 and Figure 6A).
Analysis of pathways induced upon PROX1 suppression dem-
onstrated strong enrichment for Gene Ontology (GO) categories
(p < 105): receptor activity, receptor binding, integral to plasma
membrane, tissue development, regulation of signal transduc-
tion, intrinsic to plasma membrane, cyclic nucleotide metabolic
process, actin binding, intercellular junction, and biological
adhesion (Table S3 and Figure S8), suggesting that suppression
of cell adhesion and regulation of actin cytoskeleton are the pri-
mary responses controlled by PROX1. Downregulated genes
were enriched in GO terms protein translation, cell metabolism,412 Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc.
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the transition to a more quiescent resting state (Table S3 and Fig-
ure S8). Despite the evident coregulation of many genes impor-
tant in the cell-cell and cell-ECM interactions, there were no sig-
nificant changes in the expression of genes associated with the
regulation of cell cycle at 48 hr (Figure 6B), suggesting that loss
of PROX1 does not directly affect cell proliferation. Loss of
PROX1 in SW480R cells also shifted the transcriptional pheno-
type toward that of SW480A cells (Table S4).
In line with the upregulation of cell-adhesion pathways,
PROX1 suppression resulted in a morphological change by 72
hr posttransfection, which persisted for at least 10 days (Fig-
ure 6C). First, PROX1 siRNA-transfected cells became more
elongated and displayed extensive membrane ruffling. Later on
they started to spread and adhere on the plate, and an increased
number of actin stress fibers could be visualized in the cells
(Figure 6C). At 120 hr posttransfection the PROX1 siRNA-trans-
fected cells proliferated at a lower rate than the GFP siRNA-
transfected cells (BrdU-positive cells: 22% ± 0.5% PROX1
siRNA A16, 18% ± 1% PROX1 siRNA A25 versus 34% ± 4%
Figure 5. Prox1 Is a Tissue-Specific Target of the b-Catenin/TCF
Pathway
(A) dnTCF4 does not repress PROX1 in HepG2 cells. Staining for dnTCF
(green), PROX1 (red), and DNA (blue).
(B) Comparable levels of Prox1 in livers of Ah-Cre; Apcflox/flox and control mice
after 6 days of b-naphtoflavone treatment.
(C) Nuclear translocation of b-catenin in hepatocytes of b-naphtoflavone-
treated Ah-Cre; Apcflox/flox but not control mice.
Scale bars, 10 mm in (A), 50 mm in (B), and 10 mm in (C).GFP siRNA), and they expressed higher levels of cell-cycle inhib-
itor p21CIP1/WAF1 (Figure S7). As changes in other gene cate-
gories preceded this event, we believe that decreased cell pro-
liferation is secondary to the acquisition of a more adhesive
phenotype upon loss of PROX1.
Growth of SW480R cells is adhesion independent, which is
a hallmark of malignant transformation. Upregulation of cell ad-
hesion upon loss of PROX1 suggested that the cells reacquired
the dependence on the signals from the extracellular environ-
ment. Indeed, PROX1 siRNA-transfected cells were not able to
form colonies in soft agar, which provides an adhesion-indepen-
dent milieu, while the cells transfected with GFP siRNA and un-
transfected controls formed a similar number of colonies (Fig-
ure 6D). Thus, loss of PROX1 shifts the transcriptional profile of
highly aggressive SW480R cells toward more quiescent pheno-
type reminiscent of SW480A cells, characterized by higher levels
of cell adhesion molecules, slower growth and metabolic rates,
and inability to grow in an adhesion-independent manner.
In Vivo Overexpression of PROX1 Promotes Intestinal
Tumor Progression
To study the in vivo role of PROX1 in CRC, we produced trans-
genic mice expressing PROX1 in intestinal epithelium under
the control of the 12.4 kb mouse villin promoter (Madison
et al., 2002; and Figures 7A and 7B). The transgenic mice did
not display obvious abnormalities of intestinal differentiation or
proliferation, although the transgenic males were slightly smaller
than their littermates (23.6 g versus 27.1 g, p = 0.0092, n = 9 for
the tg and 10 for the WT, age 2 months). The villin-PROX1 mice
did not develop intestinal tumors, at least when analyzed at the
age of 1 year (n = 6 for WT or tg, data not shown), indicating
that PROX1 overexpression alone is not sufficient to drive the on-
cogenic process. However, upon treatment with the colon car-
cinogen AOM, the villin-PROX1 mice developed significantly
more numerous and larger intestinal adenomas in comparison
to the wild-type littermates (Figures 7C and 7D). Notably, 9 out
of 14 transgenic mice developed at least one macroscopical le-
sion (>1 mm3, range 1.2–5.6 mm3), while no large lesions were
detected in any of the wild-type mice (n = 12, Figure 7D).
The colonic neoplasms in both wild-type and transgenic mice
were adenomas, many of which extended through the lamina
propria but showed no invasion of muscularis mucosae. Notably,
38% of the tumors from the villin-PROX1 transgenic mice con-
tained high-grade dysplasia or carcinoma in situ (5/13 tumors
studied) versus only 10% in the wild-type mice (1/10). We did
not observe obvious differences in tumor cell proliferation or ex-
pression of neuroendocrine markers, as determined by staining
of tumors of comparable size for phosphohistone H3 and chro-
mogranin A. Interestingly, the number of preneoplastic ACFs
was similar in the wild-type and transgenic mice (28.9 ± 9.0
versus 24.1 ± 6.7, p = 0.14, n = 11 and 14). Since ACFs are the
putative precursors of CRC, these data support our hypothesis
that PROX1 is important for tumor establishment and progres-
sion but not for tumor initiation.
Suppression of PROX1 in Colon Cancer Cells
Inhibits Tumor Growth
Next we asked whether loss of PROX1 affects CRC develop-
ment in vivo. We downregulated PROX1 mRNA in usingCancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc. 413
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SW480R cells. Doxycycline treatment significantly reduced
PROX1 expression, as well as the size and incidence of the
SW480/PROX1si tumors in nu/nu mice, but it had no effect
on SW480/GFPsi tumors (Figures 7E and 7F and Table S5). De-
creased tumor growth was observed when the doxycycline
treatment was initiated either immediately after implantation
or 2 weeks later. Similarly, PROX1 suppression significantly in-
hibited growth of the PROX1-positive COLO205 CRC cells in vivo,
but not in vitro (Figures 7G and 7H and data not shown).
Loss of Prox1 Inhibits Tumor Progression
in Apcmin/+ Mice and Leads to Re-Establishment
of Cell Polarity and Quiescence
Because of potential caveats associated with the gene silencing
approach, we studied whether genetic loss of Prox1 affects
the development of intestinal polyposis in Apcmin/+ mice.
We crossed mice with a conditionally targeted Prox1 allele
(Prox1flox/flox [Harvey et al., 2005]) with villin-Cre mice (Madison
et al., 2002) and Apcmin/+ mice, confirmed an efficient deletion
of Prox1 in intestinal epithelial cells and adenomas (Figure S9),
and then monitored the incidence and size of intestinal lesions
Figure 6. PROX1 Controls Cell Adhesion
Program in CRC
(A) Loss of PROX1 significantly changes the ex-
pression of 148 genes. Significantly changed
genes (corrected p < 0.05) are shown in red (upre-
gulated) and green (downregulated) in the Volcano
plot. Vertical lines mark the 2-fold change limits,
and the horizontal line marks the cut-off for statis-
tical significance.
(B) Loss of PROX1 results in the coordinate regu-
lation of cell adhesion genes at 48 hr, while no
significant changes are observed in cell-cycle-
related genes. Heat maps show results of two-
dimensional hierarchical clustering of samples
and the 23 significantly differentially expressed
probe sets targeting genes involved in cell adhe-
sion or a selected set of cell-cycle-related genes.
(C) Loss of PROX1 induces changes in the actin
cytoskeleton. Staining with falloidin 120 hr and
240 hr after PROX1 siRNA A16 or control A18
transfection.
(D) Loss of PROX1 prevents growth in soft agar.
SW480R cells were transfected with GFP siRNA,
PROX1si RNA A16, or PROX1 siRNA A25 or left
untreated (NT) and seeded in soft agar, and the
colonies were scored after 2 weeks. Data are
shown as mean ± SEM.
Scale bar, 10 mm.
in the triple transgenic mice (DProx1) ver-
sus the control wild-type and heterozy-
gous littermates.
We quantified the number and size
of intestinal polyps using whole-mount
staining of intestinal epithelium with
methylene blue, which highlights both mi-
cro- and macroscopic lesions. There was
a strong reduction in the number of mac-
roscopically visible lesions and tumor size (Figure 8A). Most no-
tably, we observed a five-fold reduction in the number of tumors
exceeding 5 mm3 (p = 0.02), while the number of microscopic le-
sions increased (Figure 8A). Since the total number of intestinal
lesions was only marginally reduced inDProx1 versus the control
mice (48.7 versus 57.1, p = 0.26), we conclude that the loss of
Prox1 does not prevent tumor initiation but instead impairs tumor
progression.
The macroscopic tumors from the wild-type mice displayed
a pleomorphic histology ranging from tubular adenomas of
low-grade dysplasia to carcinoma in situ. The neoplastic tubules
of the wild-type tumors contained enlarged, rounded nuclei, and
frequent mitotic figures were readily observed in the luminal por-
tion of the dysplastic epithelium. The dysplastic glands occurred
frequently in a ‘‘back-to-back’’ organization and contained tu-
mor cells with defective polarity (Figure 8B and Figure S9). In
contrast, DProx1 tumors consisted of monomorphic, well-orga-
nized large glands separated by an abundant fibromuscular
stroma. (Figure 8B and Figure S9). These glands contained uni-
formly sized, well-polarized, and tightly packed cells with elon-
gated nuclei and infrequent mitotic figures. The rate of apoptosis
did not differ between the wild-type and DProx1 tumors as414 Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc.
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PROX1 Promotes Colorectal Tumor Progressiondetermined by staining for active caspase 3 (data not shown).
DProx1 tumors, however, showed low frequency of mitotic fig-
ures and almost 70% reduction of cells stained for the prolifera-
Figure 7. PROX1 Is Necessary for Tumor Growth In Vivo
(A) PROX1 expression in intestines of the villin-PROX1 transgenic and wild-
type mice. Northern and western blotting for the indicated mRNA and proteins.
28S and 18S RNA and villin are used as loading controls.
(B) Expression pattern of PROX1 transgene and endogenous Prox1 in mouse
colon. Arrowheads: Prox1-positive lymphatic vessels. Arrows: Prox1-positive
cells in the crypt compartment.
(C) Increased tumor multiplicity and tumor load in AOM-treated villin-PROX1
transgenic mice. n = 12 and 14 for the WT and tg mice. *p < 0.05; **p < 0.01;
data are shown as mean ± SEM.
(D) Tumor size distribution in villin-PROX1 transgenic and wild-type mice.
Numbers above bars indicate percentage of tumors.
(E and F) Loss of PROX1 inhibits growth of SW480R tumor xenografts. Similar
results were obtained with two independent clones of SW480R/PROXsi cells.
(G and H) PROX1 downregulation inhibits growth of COLO205 xenografts.
In (E)–(G), n = 10 per experimental group; data are shown as mean ± SEM.
Scale bars, 25 mm.tion marker Ki67 (Figure 8C). The nuclei of DProx1 cells were
darker and the nucleoli were smaller in comparison to the control
tumor nuclei (Figure 8B). Since increased nucleolar size is linked
to ribosome biogenesis and cell transformation (Ruggero and
Pandolfi, 2003), these finding suggest a reduced protein synthe-
sis rate in DProx1 cells, which is in agreement with downregula-
tion of protein translation pathways in PROX1 siRNA-treated
cells and further confirms the transition of Prox1 deficient cells
toward a quiescent state.
Differentiation toward the goblet cell lineage via suppression
of the Notch pathway blocks cell proliferation in Apcmin/+ adeno-
mas (van Es et al., 2005). We therefore studied whether loss of
Prox1 affected tumor differentiation status. DProx1 and control
adenomas contained no enteroendocrine and few goblet and
Paneth cells, and the expression of villin was strongly reduced
in comparison to the normal mucosa (Figure S9 and data not
shown). These data suggested that the loss of Prox1 does not
promote cell differentiation. However, DProx1 neoplastic cells
had a continuous apical staining for villin, while its localization
was frequently discontinuous, patchy, or completely absent in
the control adenomas (Figure 8D). Furthermore, while abundant
cytoplasmic/nuclear b-catenin was present in both DProx1 and
the control tumors, higher levels of b-catenin could be found in
cell-cell junctions inDProx1 adenomas (Figure 8E). The better or-
ganization of DProx1 glands and upregulation of cell adhesion
pathways in gene-expression analysis suggested re-establish-
ment of cell-ECM interactions. Indeed, staining for collagen IV,
fibronectin, and laminin revealed well-organized basement
membranes around the DProx1 adenomas (Ø > 2 mm), which
were more similar to the ones around the normal nontransformed
intestinal epithelium than to the wild-type adenomas of the same
size (Figure 8F, Figure S9, and data not shown). As these differ-
ences were observed in tumors of similar size, they did not result
from the analysis of tumors at different stages, i.e., microscopic
versus macroscopic lesions. We therefore conclude that the
deletion of Prox1 in intestinal adenomas leads to a quiescent
phenotype, characterized by preservation of cell polarity, better
organization of basement membranes, and strong reduction
in cell proliferation, which ultimately prevents tumor growth
and progression toward a more malignant phenotype.
DISCUSSION
Our study shows that the PROX1 homeobox transcription factor
marks the transition from benign colon adenoma to carcinoma in
situ and that its misexpression promotes tumor progression in
CRC models in mice. These results demonstrate a role for this
developmentally important transcription factor in cancer and
show that PROX1 acts as an essential downstream effector of
TCF/b-catenin signaling in CRC. Until recently, PROX1 was
mostly studied in the context of embryonic development.
Prox1 was shown to control the development of the lymphatic
vasculature, lens fiber cells, and liver and retinal progenitor cell
differentiation (Dyer et al., 2003; Sosa-Pineda et al., 2000; Wigle
et al., 1999; Wigle and Oliver, 1999). One previous study has re-
ported increased PROX1mRNA in colorectal tumors, but the au-
thors attributed this to increased lymphangiogenesis (Parr and
Jiang, 2003). In contrast, we show here that, in addition to lym-
phatic vessels, PROX1 is highly expressed in the CRC cells.Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc. 415
Cancer Cell
PROX1 Promotes Colorectal Tumor ProgressionFigure 8. Intestinal-Specific Deletion of Prox1 Inhibits Tumor
Progression in Apcmin/+ Mice
(A) Deletion of Prox1 reduces macroscopic tumor load in small intestines of
Apcmin/+ mice (n = 8, WT, and n = 11, DProx1, age 24 weeks).
(B) Altered cell morphology in macroscopic DProx1 tumors. Note preservation
of cell polarity and elongated nuclei in DProx1 versus the control tumors.
(C) Reduced cell proliferation in DProx1 versus the WT tumors. Five tumors
(Ø = 2 mm) from three animals of each genotype (15 total/genotype) were
used to calculate Ki67 proliferation index.
(D–F) (D) Preservation of apical-basal polarity in macroscopic DProx1 tumors
(Ø > 2 mm). Staining for apical marker villin (green) and DNA (blue). (E) In-
creased b-catenin in cell-cell junctions of DProx1 tumors. Note similar levels
of b-catenin in normal glands of the wild-type and DProx1 tumors (asterisks).
(F) Better preservation of basement membrane in DProx1 tumors. Staining for
fibronectin (red) and DNA (blue). For (D)–(F), five to ten tumors of similar size
per genotype were examined.
(G) A model for PROX1 role in CRC. Following loss of Apc and activation of
TCF/b-catenin signaling, intestinal epithelial cells begin to proliferate and ex-
press genes associated with the intestinal progenitor cell program. C-myc is416 Cancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc.Our data indicate a gain of function via PROX1 expression,
which contrasts with the reported tumor suppressor role for
Prospero in Drosophila (Betschinger et al., 2006). Asymmetric
distribution of Prospero during larval neuroblast division inhibits
the self-renewal of one of the daughter cells and maintains a bal-
ance between the neuroblast stem-like cell population and gan-
glion mother cells that give rise to neurons. Loss of Prospero
shifts the balance toward uncontrolled proliferation through
loss of control of cell-cycle genes, such as dcycE and leads to
formation of tumors with neuroblastoma-like features (Bet-
schinger et al., 2006; Caussinus and Gonzalez, 2005). In mice,
Prox1 controls cell-cycle exit of mouse retinal progenitor cells
and promotes horizontal-cell fate, loss of Prox1 increases the
proliferation of lens fiber cells, and Prox1 also participates in
the production of ‘‘secondary transition’’ pancreatic endocrine
cells (Dyer et al., 2003; Wang et al., 2005; Wigle et al., 1999).
We found that Prox1 is expressed in the Ngn3+ progenitor cells
as well as in a subset of mature enteroendocrine cells in the in-
testinal epithelium. Its function in these cells is likely to be evolu-
tionarily conserved, as Prospero expression identifies enteroen-
docrine cells in Drosophila midgut (Ohlstein and Spradling,
2007). In mammals, enteroendocrine cells are composed of at
least 15 different subpopulations. Previous work suggests the
existence of two pathways for enteroendocrine differentiation,
one producing serotonin and substance P, and another express-
ing PYY, CCK, neurotensin, and GLP-1 (Roth et al., 1992). Prox1
is preferentially expressed in the latter cells, and we speculate
that one of the functions of Prox1 in the normal intestinal epithe-
lium is the regulation of enteroendocrine progenitor commitment
to one of the two pathways.
In contrast to Drosophila ganglion mother cells, vertebrate ret-
inal progenitors, or gut enteroendocrine cells, we find that Prox1
is highly expressed in cultured, actively proliferating CRC cells
and in intestinal adenomas. Moreover, downregulation or dele-
tion of PROX1 inhibits tumor progression, while PROX1 overex-
pression potentiates colonic adenoma development. These re-
sults demonstrate that, in the context of oncogenic signaling,
PROX1 contributes to tumor progression. We suggest that, in
colon cancer, Prox1 activity is integrated into genetic circuits
other than regulation of the cell cycle and terminal differentiation,
and that in dysplastic intestinal epithelial cells this function man-
ifests as abnormal control of cell adhesion, ECM interactions,
and cell polarity. This conclusion is based on several observa-
tions. First, Prox1-positive cells in CRC do not express neuroen-
docrine markers that are coexpressed with Prox1 in normal cells,
and loss of Prox1 does not lead to differentiation toward any
specific cell lineage. Furthermore, PROX1 overexpression in
PROX1-negative CRC cells does not promote cell-cycle exit or
neuroendocrine phenotype (T.V.P., unpublished data). Second,
PROX1 suppression in vitro does not directly affect cell-cycle
regulators, but instead induces genes associated with cell
a direct target of TCF/b-catenin that controls most of downstream effects of
this pathway. Prolonged and high TCF/b-catenin activation, possibly in coop-
eration with other events, induces Prox1 in the initiated progenitor cells, which
leads to the suppression of cell dependency on cell-cell and cell-ECM con-
tacts, loss of cell polarity and tissue architecture, further uncontrolled prolifer-
ation, and establishment of macroadenomas and carcinomas in situ.
Data in (A) and (C) are shown as mean ± SEM. Scale bars, 25 mm.
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leads to the cell reprogramming toward an adhesion-dependent
and quiescent phenotype. Finally, decreased tumor cell prolifer-
ation alone upon deletion of cell-cycle regulator cyclin D1 in
Apcmin/+ mice leads to a different phenotype, characterized by
a lack of changes in tumor cell morphology and a reduction in tu-
mors at all stages (Wilding et al., 2002). Therefore, we suggest
that Prox1 contributes to tumor progression by disrupting tissue
architecture, cell polarity, and adhesion, which in the context of
oncogenic Wnt signaling leads to spatially unrestricted cell
proliferation. Our preliminary comparison of gene expression
profiles following loss of b-catenin versus loss of Prox1 in CRC
cells shows that Prox1 controls a functionally distinct subset of
b-catenin-responsive genes (unpublished data).
What controls the expression of Prox1 in tumors? We propose
that, during the genesis of colon cancer, PROX1 expression is
triggered in response to abnormally high and prolonged TCF/
b-catenin signaling. In these conditions, PROX1 acts as a switch
converting the original ‘‘normal progenitor’’ TCF/b-catenin pro-
gram, in which the progenitor cells are still responsive to extra-
cellular signals from underlying basement membrane and are
relatively well polarized, to the ‘‘adenomatous progenitor’’
TCF/b-catenin program, in which cells are able to survive and
proliferate under unfavorable conditions, despite cell crowding,
growth inhibitory signals from stromal cells, decreased ECM ad-
hesion, and loss of cell polarity (Figure 8G). This would increase
retention of adenomatous cells in the tissue, further predisposing
them to the accumulation of harmful genetic changes, such as
KRAS and P53 mutations that lead to the development of full-
blown colon cancer. This hypothesis is consistent with the ex-
pression of Prox1 in adenomatous cells, but not in expanded
progenitors upon Apc deletion in vivo, high PROX1 levels in hu-
man high-grade dysplastic lesions, inability of cancer cells to
form colonies in soft agar or tumors in vivo upon loss of Prox1,
and potentiation of tumor growth and progression, but not tumor
initiation in villin-PROX1 transgenic mice.
A remaining outstanding question is the exact mechanism of
PROX1 action in colon cancer. The molecular effectors of this
transition remain to be elucidated. PROX1 modifies the expres-
sion of at least 150 genes in vitro, and we believe that the ob-
served effect of PROX1 on the development of colon tumors is
likely to be due to changes in the transcription of many genes,
rather than of any single ones. Thus, further studies, such as
identification of the direct PROX1 target genes in CRC, are nec-
essary to elucidate the molecular details of PROX1 function in
this disease. Knowledge of direct Prox1 targets in diverse mam-
malian cell types and comparison with targets of Prospero in
Drosophila should provide the basis for a detailed understanding
of the evolutionarily conserved, as well as divergent, pathways
controlled by this transcription factor in normal and cancer cells.
One common theme regarding the function of Prox1 is the im-
portance of the cellular context. Indeed, a comparison of the
genes regulated by PROX1 in lymphatic endothelial, colon, and
liver cancer cells shows very little overlap, demonstrating that
PROX1 controls highly specific transcriptional programs in
each context (our unpublished data). The control of PROX1 ex-
pression is itself highly tissue specific, as b-catenin/TCF signal-
ing strongly induces Prox1 in the intestinal epithelium but has lit-
tle effect in hepatocytes. These results demonstrate importanttissue-specific differences in signaling downstream of the acti-
vated Wnt pathway in cancers of the intestine and liver. Such
cell type-specific responses are likely to be important determi-
nants of tumor progression in these organs. We identified a con-
served 350 bp element 49 kb upstream of the PROX1 transcrip-
tion start site, which contains TCF/LEF binding sites that confer
the responsiveness to Wnt signaling in vitro. This region also
contains conserved binding sites for RORa, SOX17, MZF1,
Snail, SPI-B, and CSL (Figure S6). Future studies, such as gen-
eration of mice with targeted deletions of these transcription fac-
tor binding sites, should identify pathways that are responsible
for tissue-specific induction of Prox1 in response to Wnt signal-
ing. Prox1 expression is also lost upon inactivation of Wnt signal-
ing in cerebellar granule cells; this could be another tissue where
the TCF/LEF-responsive enhancer participates in Prox1 tran-
scription (Zhou et al., 2004).
In conclusion, our results show that PROX1 does not act as
a tumor suppressor in colon cancer; conversely, its expression
is activated in response to abnormally elevated oncogenic
TCF/b-catenin signaling in intestinal epithelium, and this overex-
pression is important for tumor progression via disruption of cell
polarity and adhesion. Our data indicate that PROX1 is not re-
quired for the early stages of tumor development, such as the mi-
croscopic initiation and expansion of preneoplastic progenitor
cells, which produce clinically benign lesions. Instead, PROX1
is important for the establishment and growth of highly dysplas-
tic in situ lesions, which, if left untreated, will inevitably progress
to cancer. We believe that these results reflect the multistage,
tissue-specific nature of the carcinogenesis process. Our results
also reinforce the concept that, during tumor progression, can-
cer cells can misconnect and integrate activities from multiple
pathways, including those linked to the differentiation of the cor-
responding normal cell types. Although an abnormally activated
Wnt pathway is the driving force in intestinal carcinogenesis, its
complete inhibition will likely cause significant side effects in
cancer patients because Wnt signaling plays an important role
in normal intestinal tissue homeostasis (Pinto et al., 2003).
Thus, silencing the activity of colon cancer-specific targets
of the Wnt pathway, such as PROX1, may represent another
strategy for fighting this difficult disease.
EXPERIMENTAL PROCEDURES
Reagents
Antibody suppliers, details of immunohistochemical procedures, and syn-
thetic RNAs (Dharmacon Research) are provided in the Supplemental
Experimental Procedures.
Cell Culture, Transfection, ChIP, Soft Agar Assay,
and EMSA Analysis
SW480, HT29, SW48, DLD1, WiDr, COLO205, HCT-116, and LS174T cells
were cultured under conditions suggested by the provider (ATCC). Subclones
of SW480 cells were derived by the limiting dilution method. Production of sta-
ble cell lines for tumor xenograft experiments is described in the Supplemental
Experimental Procedures. ChIP was performed as described (O’Geen et al.,
2006). For soft agar assay, 2 3 103 cells were seeded in triplicate in 1 ml of
0.33% (w/v) agar (Difco) in complete D-MEM medium in 6-well plates on 1 ml
of a 0.5% bottom agar layer. Cells were fed twice a week, and the number of
colonies per well was scored 2 weeks later. EMSA was carried out using 50-bi-
otinylated DNA oligonucleotides containing a 9 bp TCF/LEF binding sequence
flanked by 10 bp of the surrounding promoter sequences; in controlCancer Cell 13, 407–419, May 2008 ª2008 Elsevier Inc. 417
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tal Experimental Procedures).
RNA Isolation, Northern and Western Blotting, and Gene
Expression Profiling
Total RNA was isolated using RNeasy columns (QIAGEN). The Cancer Pro-
filing Array (Clontech) was hybridized with 32P-labeled probes for LYVE-1
(AF118108) and PROX1 (NM002763), and the signals were normalized to
that of GAPDH. Northern blots were hybridized with 32P-labeled probes (see
Supplemental Experimental Procedures), and western blots were developed
using the ECL method.
For the analysis of differential gene expression, RNA was isolated from two in-
dependent clones of SW480R or SW480A cells. For the analysis after PROX1
knockdown, SW480R cells were transfected with PROX1 siRNA A16 or A25
or GFP siRNA A18; RNA was isolated 48 hr later and processed for array hybrid-
ization, data validation, and pathway analysis (see Supplemental Experimental
Procedures). Microarray data were submitted to MIAMExpress at the European
Bioinformatics Institute, Hinxton, UK (http://www.ebi.ac.uk/arrayexpress/) un-
der the experimental accession number E-MEXP-1422.
In Vivo Experiments
Experiments were approved by the Helsinki University Ethics Committee. Gen-
otyping was as described (Harvey et al., 2005; Sterner-Kock et al., 2002; Su
et al., 1992). Apcmin/+ and villin-Cre mice (Jackson laboratories) were on the
C57BL6J background, and Prox1flox/flox mice were bred for five generation
to the C57BL6J background. For tumor xenografts, nu/nu NMRI male mice
were injected subcutaneously with 1 3 106 SW480R/si cells or 2 3 106
COLO205/si cells, and tumors were allowed to grow for up to 5 weeks. Doxy-
cycline (1 mg/ml) in 0.5% sucrose was administered in drinking water after in-
jection or 2 weeks later; the control group received 0.5% sucrose. Tumor size
was calculated as length 3 width2 3 0.52. Villin-PROX1 transgenic mice on
FVB/N background expressed PROX1 cDNA under the 12.4 kb mouse villin
promoter. Mice were genotyped by PCR using the following primers:
50-CCGGGTGGGCAGGGTAGAGG, 50-ACAGCTGGGAAATTATGGTTGC.
AOM Treatment and Intestinal Tumor Analysis
Six-month-old transgenic and littermate wild-type mice received five weekly
injections of 10 mg/kg of AOM (Sigma) and were sacrificed 10 weeks after
the last injection. Large (AOM treatment) and small (Apcmin/+ analysis) intes-
tines were slit open, mounted flat, fixed in 4% PFA, stained with 0.1% methy-
lene blue, and analyzed using published guidelines (Boivin et al., 2003) by two
observers (T.V.P. and A.N.). Histological scoring was without knowledge of the
genotype by an experienced pathologist (L.C.A.).
Statistical Analysis
A two-tailed, unpaired Student’s t test was done to determine statistical signif-
icance by the probability of difference between the means. p < 0.05 is consid-
ered statistically significant. Values in the graphs are expressed as means ±
SEM or SD.
ACCESSION NUMBERS
Microarray data were submitted to MIAMExpress at the European Bioinfor-
matics Institute, Hinxton, UK (http://www.ebi.ac.uk/arrayexpress/) under the
experimental accession number E-MEXP-1422.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, nine
supplemental figures, and five supplemental tables and can be found with this
article online at http://www.cancercell.org/cgi/content/full/13/5/407/DC1/.
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